Latest From Cellnovo Group
The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?
The global infusion drug delivery market continues to be driven by the rising prevalence of chronic disease and associated obesity, coupled with a growing aging population. Technological advancements such as less invasive pumps, needlestick prevention features and miniaturization have also supported the growing demand, but obstacles such as safety and security issues remain. According to a new report by Meddevicetracker, the global market for infusion pumps and disposables will reach $9.9bn by 2022, a CAGR of 6.4% from 2017. This article takes an in-depth look at the overall infusion pumps market, and dives deeper into the three fastest-growing segments – insulin, enteral and disposable pumps – highlighting the key players and competitive landscape.
Edmond De Rothschild Investment Partners unveils the largest life science and medical device venture fund to be raised in Europe. Olivier Litzka tells Scrip that the continent can now boast a public market machinery that contributes to potentially lucrative exits for investors.
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.
In Vitro Diagnostics
- Glucose Testing
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- Cellnovo Ltd.
- Western Europe
- Parent & Subsidiaries
- Cellnovo Group
- Senior Management
Sophie Baratte, CEO
Thierry Moulin, CFO
Julian Shapley, CSO
- Contact Info
Phone: (44) (0) 1 78 42 40 2
13 rue de Londre
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.